Savara Inc (NASDAQ:SVRA)
| Market Cap | 958.03M+34.7% |
| Revenue (ttm) | 0 |
| Net Income | -139.31M-26.3% |
| EPS | -0.58-13.7% |
| Shares Out | 204.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 303,127.023 |
| Open | 4.85 |
| Previous Close | 4.88 |
| Day's Range | 4.63 - 4.92 |
| 52-Week Range | 3.35 - 7.01 |
| Beta | 0.25 |
| Analysts | Buy |
| Price Target | 10.00(+113.90%) |
| Earnings Date | Nov 11, 2026 |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About SVRA
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$SVRA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in SVRA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SVRA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SVRA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SVRA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SVRA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SVRA
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $33.23M |
| IWMiShares Russell 2000 ETF | $19.65M |
| XBIState Street SPDR S&P Biotech ETF | $15.51M |
| VXFVanguard Extended Market ETF | $8.57M |
| IWOiShares Russell 2000 Growth ETF | $6.94M |
| VTWOVanguard Russell 2000 ETF | $4.74M |
Estimated from each fund’s disclosed top holdings × AUM
SVRA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SVRA’s recent data — informational, not investment advice